Exelixis and arcus biosciences announce clinical trial collaboration to evaluate zanzalintinib in combination with ab521 in patients with advanced renal cell carcinoma

Alameda, calif. and hayward, calif.--(business wire)--exelixis, inc. (nasdaq:exel) and arcus biosciences (nyse:rcus) today announced that the companies have entered into a clinical trial collaboration for stellar-009, a phase 1b/2 trial evaluating zanzalintinib, exelixis' next-generation tyrosine kinase inhibitor (tki), in combination with ab521, an inhibitor of the transcription factor hif-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccrcc). exelixis i.
RCUS Ratings Summary
RCUS Quant Ranking